Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Capital Expenditures (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Capital Expenditures for 16 consecutive years, with -$1000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures changed N/A to -$1000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $34000.0 through Dec 2025, down 76.06% year-over-year, with the annual reading at $34000.0 for FY2025, 76.06% down from the prior year.
  • Capital Expenditures hit -$1000.0 in Q4 2025 for Ironwood Pharmaceuticals, down from $2000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $211000.0 in Q4 2023 to a low of -$27000.0 in Q4 2022.
  • Historically, Capital Expenditures has averaged $47533.3 across 5 years, with a median of $31000.0 in 2025.
  • Biggest five-year swings in Capital Expenditures: plummeted 121.09% in 2022 and later skyrocketed 881.48% in 2023.
  • Year by year, Capital Expenditures stood at $128000.0 in 2021, then tumbled by 121.09% to -$27000.0 in 2022, then surged by 881.48% to $211000.0 in 2023, then plummeted by 92.42% to $16000.0 in 2024, then plummeted by 106.25% to -$1000.0 in 2025.
  • Business Quant data shows Capital Expenditures for IRWD at -$1000.0 in Q4 2025, $2000.0 in Q3 2025, and $2000.0 in Q2 2025.